GlassScriptPhysician profile
Adel Youssef Armanious
NPI 1417920695
$2,200.17
in general payments reported to CMS, 2019-2025
26 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $193 · 2021: $393 · 2022: $210 · 2023: $327 · 2024: $344 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $556.85 | 2019-2024 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $410.21 | 2023-2025 | Lifevest |
| Glaxosmithkline, LLC. | $169.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $139.48 | 2019-2024 | |
| Amgen INC. | $109.56 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $107.97 | 2020-2024 | Verquvo |
| Boston Scientific Corporation | $74.37 | 2019-2022 | |
| Baxter Healthcare | $64.92 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $58.52 | 2019-2022 | |
| Medtronic, INC. | $49.86 | 2021-2025 | Minimed 780g |
| Lilly USA, LLC | $49.19 | 2024 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $49.09 | 2025 | Cologuard Collection Kit |
| Atricure, INC. | $46.56 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $43.60 | 2020-2021 | |
| Dexcom, INC. | $42.91 | 2021-2024 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $40.82 | 2019 | |
| Biogen, INC. | $26.71 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.65 | 2019 | |
| Cvrx, INC. | $19.64 | 2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $19.21 | 2020 | |
| Gilead Sciences, INC. | $18.90 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.59 | 2024 | Rexulti |
| Philips North America LLC | $17.98 | 2022 | |
| Amarin Pharma, INC. | $14.64 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.33 | 2024 | Breztri |
| Esperion Therapeutics, INC. | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Armanious listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.